Form 4: Ultragenyx CFO Howard Horn Acquires Shares and Stock Options

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, reports acquisition of common stock and stock options.

Summary

• On March 1, 2024, Howard Horn, the CFO of Ultragenyx Pharmaceutical Inc., acquired 19,400 shares of common stock through a Restricted Stock Unit (RSU) award.
• These RSUs vest in equal installments over four years.
• Horn also acquired 34,200 stock options with an exercise price of $53.69, vesting over a period of 4 years.
• Following these transactions, Horn directly owns 99,766 shares of common stock and 34,200 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CFO's acquisition of shares and options suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by the CFO signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the RSUs and stock options suggests a long-term commitment from the CFO.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
• The vesting schedules described are typical for such grants, encouraging long-term commitment and performance.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they reflect the CFO's confidence in the company's future.

Key Dates